This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H2, 2015 Pipeline Review of “Acute Renal Failure” addition with 42 market data tables and 14 figures, spread across 131 pages is http://www.rnrmarketresearch.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2015-market-report.html .
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research:
A1M Pharma AB, Adrenomed AG, Am-Pharma B.V., Angion Biomedica Corp., Bolder Biotechnology, Inc., Cellmid Limited, Complexa, Inc., DiaMedica Inc., Digna Biotech, S.L., DURECT Corporation, F. Hoffmann-La Roche Ltd., G1 Therapeutics, Inc., Hadasit Medical Research Services & Development Ltd, Kringle Pharma, Inc., NephroGenex, Inc., NeuroVive Pharmaceutical AB, Noorik Biopharmaceuticals AG, Nyken BV, Opsona Therapeutics Limited, Orion Oyj, ProMetic Life Sciences Inc., Quark Pharmaceuticals, Inc., STATegics, Inc., Thrasos, Inc. and Torrent Pharmaceuticals Limited
Drugs Profile Discussed in this Research:
A1M-001, adrecizumab, BB-3, BBT-030, BBT-045, CAB-101, Cardiotrophin-1, Cell Therapy to Activate Wnt7b for Kidney Injury, CXA-10, cyclosporine, DM-199, DUR-928, HYPER-IL-6, KP-100IT, levosimendan, MTP-131, N-003, NYK-1341, OPN-305, PBI-4419, pyridoxamine dihydrochloride, QPI-1002, R-190, Recombinant Human Alkaline Phosphatase, Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury, RLS-003, RO-6839328, Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer, Small Molecule to Inhibit HDAC for Acute Kidney Injury, STSE-15, THR-184 and TRC-160334
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=439322 . (This is a premium report price at US$2000 for a single user PDF license)
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Renal Therapeutics Market.
The renal disease therapeutics market supports with the increase in the number of kidney transplantation, improvement in drug treatments and building stronger patient confidence in the procedure. Also, the options are available to treat the diseases by using novel drugs with other new technology, such as stem cell therapy and immunoglobulin therapy.
Most of the renal disease global market revenues inncreased due to the approval of pipeline products, introduction of new therapies such as antioxidant inflammatory modulators, metal-free phosphate binders and the products in the filing or later stage development phase. In the near future, the companies are developing eight molecules which are in various clinical development stages.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.